ADMA Biologics, Inc. (ADMA)

Over the past six months, ADMA Biologics' stock price decreased by 10.52% in the past month but increased by 21.65% over the past three months and 7.34% over the last 12 months. In late 2025, ADMA achieved FDA lot release of yield-enhanced production batches, expected to boost per-batch output by 20% or more. In December 2025, ADMA divested three plasma centers for $12 million and entered into long-term plasma supply agreements. In January 2026, ADMA announced preliminary unaudited full-year 2025 total revenue of approximately $510-$511 million, increased its 2026 revenue outlook to approximately $635 million, and raised its adjusted EBITDA guidance for 2026 to approximately $360 million. ADMA provided initial guidance for 2027, projecting approximately $775 million in revenue and $455 million in adjusted EBITDA, with a long-term target of over $1.1 billion in annual revenue by 2029.

Specific details regarding the seasonal demand patterns for ADMA’s products and services are not explicitly provided. The company's products, such as immune globulins, are used to treat immunodeficiencies and prevent infectious diseases, which could imply some level of seasonality related to infection rates, but this is not detailed.

ADMA Biologics, Inc. is a biopharmaceutical company focused on manufacturing, marketing, and developing specialty plasma-derived biologics for immunodeficient patients and those susceptible to infectious diseases. Its FDA-approved products include BIVIGAM for primary humoral immunodeficiency, ASCENIV for primary immunodeficiency disease, and NABI-HB for hepatitis B immunity. The company also operates FDA-approved source plasma collection facilities through its subsidiary, ADMA BioCenters.

ADMA Biologics primarily operates within the United States, with its headquarters in Ramsey, New Jersey, and its primary manufacturing site in Boca Raton, Florida. It also has a network of FDA-approved plasma collection centers across the U.S. As of December 2025, ADMA owns and operates seven internal plasma collection centers.

ADMA Biologics has generally maintained a positive brand reputation due to strong financial performance and strategic advancements, including robust revenue growth and increasing demand for ASCENIV. The company's commitment to ethical conduct and transparency is emphasized. Potential challenges include dependence on key products, operational and regulatory risks, competitive pressures, and a Beneish M-Score of 2.2 indicating potential financial manipulation.

ADMA Biologics, Inc. has significant institutional ownership, with approximately 75% to 80.1% of the company's stock held by institutional investors, including BlackRock, Inc., Vanguard Group Inc, iShares Core S&P Small-Cap ETF, State Street Corp, Invesco Ltd., Sachem Head Capital Management LP, Geode Capital Management, Llc and Nuveen, LLC. Individual investors, along with public companies, hold a smaller portion of the stock, around 2.54% to 27.60%.